Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06851858 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06851858 · ClinicalTrials.gov record · last posted 2026-03-03

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Study acronym: ARAY
StatusActive, Not Recruiting
PhasePhase 2
Started2025-03-12
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 3, 2026 (before its estimated May 27, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.

Amendment record 6 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 6 times since 2025-02-24; most recent amendment 2026-03-02. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-03-02
Status change Recruiting→Active, Not Recruitingv6
2025-04-09
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06851858
Lead Sponsor AstraZeneca
Conditions Endocrinology, Diabetes, Type II, Obesity
Enrollment 69 participants
Start Date 2025-03-12
Primary Completion 2026-05-27 (estimated)
Study Completion 2026-05-27 (estimated)
Updated on ClinicalTrials.gov 2026-03-03